Pharmaceutical Reactivation of Attenuated Apoptotic Pathways Leads to Elimination of Osimertinib Drug-Tolerant Cells

Matthew J. Martin(Stony Brook University Hospital), Paul D. Smith(Epworth Hospital)

Cancer Research Communications

September 12, 2022

10.1158/2767-9764.crc-22-0066

Cited by 8

Related Papers

<i>RAS</i> Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors

|New England Journal of Medicine|2012|1k

The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models

|British Journal of Cancer|2012|111

Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase

|Breast Cancer Research|2014|70